Prevalence and associated factors related to sarcopenia in people living with HIV/AIDS.
AIDS
Prevalence
Sarcopenia
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
09 Sep 2024
09 Sep 2024
Historique:
received:
26
12
2023
accepted:
30
08
2024
medline:
10
9
2024
pubmed:
10
9
2024
entrez:
9
9
2024
Statut:
epublish
Résumé
The use of antiretrovirals has increased the survival of People Living with HIV/AIDS (PLWHA), resulting in an aging population and a rise in the incidence of sarcopenia. The lack of uniformity among the prevalences found in studies may be associated with the use of different diagnostic criteria, highlighting the need for local studies to determine the prevalence of sarcopenia. Cross-sectional study to estimate the prevalence and associated factors of sarcopenia using the revised criteria of the European Working Group on Sarcopenia in Older People (EWGSOP2). This study included PLWHA of both sexes, aged 40 years or older, who were treated at the infectious disease outpatient clinic of a tertiary hospital from 2019 to 2021. Muscle mass was quantified through electrical bioimpedance, using resistance and reactance to calculate appendicular lean mass (ALM) in kg/m². Muscle strength, measured in kg, was assessed using a manual dynamometer, and muscle function was evaluated using the gait speed test (m/s). Numerical variables were analyzed using measures of central tendency and dispersion. The chi-square test was used to assess associations in categorical variables. Odds ratios (OR) and 95% Confidence Intervals (CI) were calculated to evaluate the strength of associations. Among the 218 PLWHA, the prevalence of sarcopenia was 8.7% (95% CI: 5.6 to 13.3). The mean age of the study population was 51.8 ± 8.3 years; 53.7% were male, 72.9% were brown/Black, 97.7% reported not using illicit drugs, and 24.8% were classified as obese. Multivariate analysis showed that the time since HIV diagnosis (P = 0.022) and the use of illicit drugs were associated with the diagnosis of sarcopenia. The prevalence of sarcopenia using the EWGSOP2 criteria was low. People with a longer duration of HIV infection and those using illicit drugs were more likely to develop sarcopenia.
Sections du résumé
BACKGROUND
BACKGROUND
The use of antiretrovirals has increased the survival of People Living with HIV/AIDS (PLWHA), resulting in an aging population and a rise in the incidence of sarcopenia. The lack of uniformity among the prevalences found in studies may be associated with the use of different diagnostic criteria, highlighting the need for local studies to determine the prevalence of sarcopenia.
METHODS
METHODS
Cross-sectional study to estimate the prevalence and associated factors of sarcopenia using the revised criteria of the European Working Group on Sarcopenia in Older People (EWGSOP2). This study included PLWHA of both sexes, aged 40 years or older, who were treated at the infectious disease outpatient clinic of a tertiary hospital from 2019 to 2021. Muscle mass was quantified through electrical bioimpedance, using resistance and reactance to calculate appendicular lean mass (ALM) in kg/m². Muscle strength, measured in kg, was assessed using a manual dynamometer, and muscle function was evaluated using the gait speed test (m/s). Numerical variables were analyzed using measures of central tendency and dispersion. The chi-square test was used to assess associations in categorical variables. Odds ratios (OR) and 95% Confidence Intervals (CI) were calculated to evaluate the strength of associations.
RESULTS
RESULTS
Among the 218 PLWHA, the prevalence of sarcopenia was 8.7% (95% CI: 5.6 to 13.3). The mean age of the study population was 51.8 ± 8.3 years; 53.7% were male, 72.9% were brown/Black, 97.7% reported not using illicit drugs, and 24.8% were classified as obese. Multivariate analysis showed that the time since HIV diagnosis (P = 0.022) and the use of illicit drugs were associated with the diagnosis of sarcopenia.
CONCLUSION
CONCLUSIONS
The prevalence of sarcopenia using the EWGSOP2 criteria was low. People with a longer duration of HIV infection and those using illicit drugs were more likely to develop sarcopenia.
Identifiants
pubmed: 39251940
doi: 10.1186/s12879-024-09845-5
pii: 10.1186/s12879-024-09845-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
933Informations de copyright
© 2024. The Author(s).
Références
Abdul Aziz SA, McStea M, Ahmad Bashah NS, Chong ML, Ponnampalavanar S, Syed Omar SF, et al. Assessment of Sarcopenia in virally suppressed HIV-infected asians receiving treatment. AIDS. 2018;32(8):1025–34.
doi: 10.1097/QAD.0000000000001798
pubmed: 29547442
Hawkins KL, Brown TT, Margolick JB, Erlandson KM. Geriatric syndromes: new frontiers in HIV and Sarcopenia. Aids. 2017;31(February):S137–46.
doi: 10.1097/QAD.0000000000001444
pubmed: 28471944
Hawkins KL, Zhang L, Ng DK, Althoff KN, Palella FJ, Kingsley LA, et al. Abdominal obesity, Sarcopenia, and osteoporosis are associated with frailty in men living with and without HIV. Aids. 2018;32(10):1257–66.
doi: 10.1097/QAD.0000000000001829
pubmed: 29794494
Wasserman P, Segal-Maurer S, Rubin DS. High prevalence of low skeletal muscle mass associated with male gender in midlife and older HIV-infected persons despite cd4 cell reconstitution and viral suppression. J Int Assoc Provid AIDS Care. 2014;13(2):145–52.
doi: 10.1177/2325957413495919
pubmed: 24067494
Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31.
doi: 10.1093/ageing/afy169
pubmed: 30312372
SeyedAlinaghi S, Ghayomzadeh M, Mirzapour P, Maroufi SF, Pashaei Z, Ali Z et al. A systematic review of Sarcopenia prevalence and associated factors in people living with human immunodeficiency virus. J Cachexia Sarcopenia Muscle. 2023;(August 2022):1168–82.
Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis. Age Ageing. 2010;39(4):412–23.
doi: 10.1093/ageing/afq034
pubmed: 20392703
pmcid: 2886201
Bonato M, Turrini F, Galli L, Banfi G, Cinque P. The role of physical activity for the management of Sarcopenia in people living with HIV. Int J Environ Res Public Health. 2020;17(4).
de Almeida LL, Ilha TASH, de Carvalho JAM, Stein C, Caeran G, Comim FV et al. Sarcopenia and Its Association with Vertebral Fractures in People Living with HIV. Calcif Tissue Int. 2020;107(3):249–56. https://doi.org/10.1007/s00223-020-00718-y
Paulino do Nascimento LC. Sarcopenia and consumptive syndrome in HIV-infected patients receiving antiretroviral therapy in a public hospital in Northeast Brazil. Rev Chil Nutr. 2020;47(3):430–42.
doi: 10.4067/S0717-75182020000300430
Lédo AP, Neves JDS, Martinez BP, Gomes Neto M, Brites C. Sarcopenia Em Uma Amostra De Indivíduos Infectados Hiv Atendidos a Nível Ambulatorial. Rev Pesqui em Fisioter. 2017;7(3):351–8. https://www5.bahiana.edu.br/index.php/fisioterapia/article/view/1536
Fess E. American Society of Hand therapists clinical Assessment recommendations. 2nd ed. Chicago: American Society of Hand Therapists; 1992.
Kyle UG, Genton L, Hans D, Pichard C. Validation of a bioelectrical impedance analysis equation to predict appendicular skeletal muscle mass (ASMM). Clin Nutr. 2003;22(6):537–43.
doi: 10.1016/S0261-5614(03)00048-7
pubmed: 14613755
Sergi G, De Rui M, Veronese N, Bolzetta F, Berton L, Carraro S et al. Assessing appendicular skeletal muscle mass with bioelectrical impedance analysis in free-living Caucasian older adults. Clin Nutr. 2015;34(4):667–73. https://doi.org/10.1016/j.clnu.2014.07.010
Graham JE. Assessing walking speed in clinical research: a systematic review. J Eval Clin Pr. 2008;14(4):552–62.
doi: 10.1111/j.1365-2753.2007.00917.x
Oliveira VHF, Borsari AL, Webel AR, Erlandson KM, Deminice R. Sarcopenia in people living with the Human Immunodeficiency Virus: a systematic review and meta-analysis. Eur J Clin Nutr. 2020;74(7):1009–21. https://doi.org/10.1038/s41430-020-0637-0
Gregson CL, Madanhire T, Rehman A, Ferrand RA, Cappola AR, Tollman S, et al. Osteoporosis, rather than Sarcopenia, is the predominant musculoskeletal disease in a rural South African community where human immunodeficiency virus prevalence is high: a cross-sectional study. J Bone Min Res. 2020;35(7):1248–58.
Oliveira VHF, Borsari AL, Cárdenas JDG, Alves Junior CM, Castro NF, Marinello PC, et al. Low agreement between initial and revised European Consensus on Definition and diagnosis of Sarcopenia Applied to people living with HIV. J Acquir Immune Defic Syndr. 2021;86(4):e106–13.
doi: 10.1097/QAI.0000000000002576
pubmed: 33230028
Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS et al. Sarcopenia in Asia: Consensus report of the Asian working group for sarcopenia. J Am Med Dir Assoc. 2014;15(2):95–101. https://doi.org/10.1016/j.jamda.2013.11.025
Dent E, Morley JE, Cruz-Jentoft AJ, Arai H, Kritchevsky SB, Guralnik J, et al. International Clinical Practice guidelines for Sarcopenia (ICFSR): screening, diagnosis and management. J Nutr Heal Aging. 2018;22(10):1148–61.
doi: 10.1007/s12603-018-1139-9
Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB et al. Sarcopenia: An Undiagnosed Condition in Older Adults. Current Consensus Definition: Prevalence, Etiology, and Consequences. International Working Group on Sarcopenia. J Am Med Dir Assoc. 2011;12(4):249–56. https://doi.org/10.1016/j.jamda.2011.01.003
Reiss J, Iglseder B, Alzner R, Mayr-Pirker B, Pirich C, Kässmann H, et al. Consequences of applying the new EWGSOP2 guideline instead of the former EWGSOP guideline for Sarcopenia case finding in older patients. Age Ageing. 2019;48(5):713–8.
doi: 10.1093/ageing/afz035
Van Ancum JM, Alcazar J, Meskers CGM, Nielsen BR, Suetta C, Maier AB. Impact of using the updated EWGSOP2 definition in diagnosing sarcopenia: A clinical perspective. Arch Gerontol Geriatr. 2020;90(May):104125. https://doi.org/10.1016/j.archger.2020.104125
de Freitas MM, de Oliveira VLP, Grassi T, Valduga K, Miller MEP, Schuchmann RA et al. Difference in sarcopenia prevalence and associated factors according to 2010 and 2018 European consensus (EWGSOP) in elderly patients with type 2 diabetes mellitus. Exp Gerontol. 2020;132(January):110835. https://doi.org/10.1016/j.exger.2020.110835
Petermann-Rocha F, Chen M, Gray SR, Ho FK, Pell JP, Celis-Morales C. New versus old guidelines for Sarcopenia classification: what is the impact on prevalence and health outcomes? Age Ageing. 2020;49(2):300–4.
pubmed: 31728486
Shafiee G, Heshmat R, Ostovar A, Khatami F, Fahimfar N, Arzaghi SM, et al. Comparison of EWGSOP-1and EWGSOP-2 diagnostic criteria on prevalence of and risk factors for Sarcopenia among Iranian older people: the Bushehr Elderly Health (BEH) program. J Diabetes Metab Disord. 2020;19(2):727–34.
doi: 10.1007/s40200-020-00553-w
pubmed: 33520799
pmcid: 7843815
Leong DP, Teo KK, Rangarajan S, Lopez-Jaramillo P, Avezum A, Orlandini A et al. Prognostic value of grip strength: Findings from the Prospective Urban Rural Epidemiology (PURE) study. Lancet. 2015;386(9990):266–73. https://doi.org/10.1016/S0140-6736(14)62000-6
Cruz-Jentoft AJ, Sayer AA, Sarcopenia. Lancet. 2019;393(10191):2636–46.
doi: 10.1016/S0140-6736(19)31138-9
pubmed: 31171417
Fisher M, Cooper V. HIV and ageing: premature ageing or premature conclusions? Curr Opin Infect Dis. 2012;25(1):1–3.
doi: 10.1097/QCO.0b013e32834f14fa
pubmed: 22183112